HCPCS (current)
J3590
NOC / invoice; no permanent J-code
Phase 1
Identify what you're billing
Confirm Casgevy vs Lyfgenia and vs AAV gene therapies; confirm SCD/TDT genetic status, recurrent VOCs / transfusion dependence, and ATC eligibility before scheduling apheresis.
Gene therapy class — Casgevy (CRISPR HSC) vs Lyfgenia (lentiviral HSC) vs Zolgensma / Hemgenix / Roctavian (AAV in-vivo) FDA labels verified May 2026
Five FDA-approved gene therapies in the CareCost catalog, four mechanisms, two billing pathway families. Don't confuse them at the claim layer.
Gene therapy is no longer a single product class. The CareCost catalog now indexes five FDA-approved gene therapies, which fall into two operationally distinct billing families:
- Ex vivo cell-based gene therapies — autologous HSCs collected by apheresis, modified at a manufacturing facility (CRISPR/Cas9 editing or lentiviral transduction), and reinfused after myeloablative conditioning. Multi-stage encounter spanning apheresis, manufacturing, conditioning, infusion, and engraftment monitoring. Casgevy (this page) and Lyfgenia are the SCD examples; CAR-T therapies (Kymriah, Yescarta, Breyanzi, Carvykti, Abecma) share this multi-stage shape but use lymphodepletion rather than myeloablation.
- In vivo AAV-based gene therapies — a single IV infusion of an AAV vector that delivers a transgene to target tissues. Single-encounter billing (one J-code + one admin CPT). The CareCost examples are Zolgensma (J3399, AAV9, pediatric SMA), Hemgenix (J1411, AAV5, hemophilia B), and Roctavian (J1412, AAV5, hemophilia A).
| Casgevy (J3590) | Lyfgenia | Zolgensma (J3399) | Hemgenix (J1411) | Roctavian (J1412) | |
|---|---|---|---|---|---|
| Mechanism | CRISPR/Cas9 edit of BCL11A enhancer (ex vivo) | Lentiviral transduction (bA-T87Q transgene, ex vivo) | AAV9 + SMN1 transgene (in vivo) | AAV5 + FIX-Padua transgene (in vivo) | AAV5 + FVIII-SQ transgene (in vivo) |
| Cell vs vector | Autologous HSC product | Autologous HSC product | AAV vector | AAV vector | AAV vector |
| Indication | SCD (recurrent VOCs); TDT | SCD (history of vaso-occlusive events) | Pediatric SMA (bi-allelic SMN1) | Adult hemophilia B (FIX ≤ 2%) | Adult hemophilia A (FVIII ≤ 1%) |
| Age (label) | ≥ 12 yr | ≥ 12 yr | < 2 yr | Adult | Adult |
| Conditioning | Busulfan myeloablation (4 d) | Busulfan myeloablation | None (in vivo) | None (in vivo) | None (in vivo) |
| Hospitalization | ~30–45 d inpatient | ~30–45 d inpatient | Planned short admission | Outpatient infusion | Outpatient infusion |
| Pre-treatment immune gate | None (autologous, no AAV) | None (autologous, no AAV) | Anti-AAV9 antibody ≤ 1:50 | Anti-AAV5 NAb (label) | Anti-AAV5 NAb (label) |
| Boxed warning | No boxed warning | Yes — hematologic malignancy | Acute liver injury / failure | No (W&P: hepatic, immunogenicity) | No (W&P: hepatic) |
| HCPCS | J3590 NOC | NOC (no permanent J-code) | J3399 permanent | J1411 permanent | J1412 permanent |
| Product list (one-time) | ~$2.2M | ~$3.1M | ~$2.125M | ~$3.5M | ~$2.9M |
| Total course (incl. facility) | ~$2.7M–$3.5M | ~$3.6M–$4.5M | ~$2.2M–$2.5M (admission) | ~$3.6M (infusion clinic) | ~$3.0M (infusion clinic) |
| Outcomes-based contracts | Common (CMS CGT Model) | Common (CMS CGT Model) | Common | Common | Common |
CRISPR vs lentivirus — why it matters for billers. At the operational billing level,
Casgevy and Lyfgenia look almost identical: same autologous apheresis collection, same ~4–6 month
manufacturing window, same busulfan myeloablation, same HSC infusion, same engraftment monitoring. The
critical differences are (1) boxed warning: Lyfgenia has a boxed warning for hematologic
malignancy (the lentiviral vector carries a small theoretical insertional-mutagenesis risk); Casgevy does
not. (2) Mechanism: Casgevy disrupts BCL11A (a transcriptional repressor of HbF), restoring
fetal hemoglobin. Lyfgenia adds a transgene encoding a modified β-globin (bA-T87Q) that polymerizes less
than HbS. (3) Payer preferences: most payers cover both, but exact PA criteria and
outcomes-based contract terms differ; some plans prefer Casgevy because of the cleaner safety label.
Once-per-lifetime constraint. Payers universally limit coverage to one autologous ex vivo
modified HSC therapy per patient lifetime. A patient who has received Casgevy is not eligible for Lyfgenia
(and vice versa). The patient is also generally not eligible for additional HSCT for SCD/TDT, allogeneic or
otherwise, except in case of engraftment failure. Document the once-per-lifetime determination in the PA
packet and the long-term follow-up plan.
Dosing & unit math FDA label verified May 2026
From the FDA-approved Casgevy prescribing information (BLA 125787; current label rev. Mar 30, 2026). Unit-of-billing is the patient-specific HSC product (one J-code event); the underlying physical dose is weight-based CD34+ cell count.
Approved indications
- Sickle cell disease (SCD) in patients ≥ 12 years with recurrent vaso-occlusive crises (VOCs). Genetic confirmation HbSS / HbSC / HbS–β-thalassemia. FDA approval December 8, 2023 — the first CRISPR-edited therapy ever approved by the FDA.
- Transfusion-dependent β-thalassemia (TDT) in patients ≥ 12 years. Genetic confirmation β-thalassemia major or HbE–β-thalassemia. FDA approval January 16, 2024.
Weight-based dosing
| Element | Value | Notes |
|---|---|---|
| Minimum dose | 3 × 10⁶ CD34+ cells/kg | Per FDA label; lower doses are not infused (insufficient engraftment risk) |
| Typical dose | 4–20 × 10⁶ CD34+ cells/kg | Driven by apheresis yield, manufacturing yield, and editing efficiency |
| Editing target | BCL11A erythroid-specific enhancer (GATA1 motif) | CRISPR/Cas9 ribonucleoprotein with sgRNA targeting BCL11A; restores HbF expression in erythroid lineage |
| Product form | Cryopreserved suspension | DMSO-containing cryopreservation medium; thawed at bedside; patient-identified bag at every step |
| Infusion duration | Per institutional HSCT protocol | Typically over 30–60 min via central line; vital signs per HSCT standard |
| Total cycles | 1 (one-time) | Per patient lifetime; not repeatable per label and payer policy |
| Age (label) | ≥ 12 years | Same age cutoff for both SCD and TDT indications |
Worked example — 60 kg adolescent with HbSS sickle cell disease and recurrent VOCs
# Calculate target dose
Weight: 60 kg
Minimum target: 3 × 10⁶ CD34+/kg × 60 kg = 1.8 × 10⁸ CD34+ cells total
Typical infused: 6–10 × 10⁶ CD34+/kg = 3.6–6.0 × 10⁸ cells total
# Multi-stage encounter timeline
Day −180 to −120: SCD diagnosis confirmation, VOC documentation, HSCT eligibility eval, fertility counseling
Day −120: Apheresis HSC collection (outpatient, ATC) — CPT 38206 / 0540T
Day −120 to −7: ex vivo CRISPR manufacturing at Vertex facility (~4–6 months)
Day −7 to −3: Busulfan myeloablative conditioning — J0594 or NOC
Day 0: Autologous HSC infusion — HCPCS J3590 + CPT 38241
Day +14 to +28: Neutrophil engraftment (ANC ≥ 500 × 3 days)
Day +30 to +45: Platelet engraftment, discharge planning
Day +60 to +365: Outpatient follow-up; HbF / HbA / Hb electrophoresis monitoring
Months 6, 12, 24, 60: Outcomes milestone reporting (Vertex Patient Support / payer OBA)
# Billing claim line (HSC infusion encounter)
Drug: J3590 · 1 unit per patient-specific HSC product (NOC; per-treatment, not per cell)
Admin: CPT 38241 (Hematopoietic progenitor cell transplant; autologous)
Apheresis (prior encounter): CPT 38206 (HSC apheresis; autologous) or 0540T (category III for HSC therapy product, autologous transplantation)
Conditioning: J-code for high-dose busulfan (J0594) or NOC
# Course cost (manufacturer WAC + facility)
Casgevy product (WAC): ~$2,200,000 (one-time)
Apheresis + manufacturing handling: ~$50,000–$100,000
Busulfan conditioning + 30–45 d inpatient: ~$400,000–$900,000+
Total course estimate: ~$2.7M–$3.5M
Weight: 60 kg
Minimum target: 3 × 10⁶ CD34+/kg × 60 kg = 1.8 × 10⁸ CD34+ cells total
Typical infused: 6–10 × 10⁶ CD34+/kg = 3.6–6.0 × 10⁸ cells total
# Multi-stage encounter timeline
Day −180 to −120: SCD diagnosis confirmation, VOC documentation, HSCT eligibility eval, fertility counseling
Day −120: Apheresis HSC collection (outpatient, ATC) — CPT 38206 / 0540T
Day −120 to −7: ex vivo CRISPR manufacturing at Vertex facility (~4–6 months)
Day −7 to −3: Busulfan myeloablative conditioning — J0594 or NOC
Day 0: Autologous HSC infusion — HCPCS J3590 + CPT 38241
Day +14 to +28: Neutrophil engraftment (ANC ≥ 500 × 3 days)
Day +30 to +45: Platelet engraftment, discharge planning
Day +60 to +365: Outpatient follow-up; HbF / HbA / Hb electrophoresis monitoring
Months 6, 12, 24, 60: Outcomes milestone reporting (Vertex Patient Support / payer OBA)
# Billing claim line (HSC infusion encounter)
Drug: J3590 · 1 unit per patient-specific HSC product (NOC; per-treatment, not per cell)
Admin: CPT 38241 (Hematopoietic progenitor cell transplant; autologous)
Apheresis (prior encounter): CPT 38206 (HSC apheresis; autologous) or 0540T (category III for HSC therapy product, autologous transplantation)
Conditioning: J-code for high-dose busulfan (J0594) or NOC
# Course cost (manufacturer WAC + facility)
Casgevy product (WAC): ~$2,200,000 (one-time)
Apheresis + manufacturing handling: ~$50,000–$100,000
Busulfan conditioning + 30–45 d inpatient: ~$400,000–$900,000+
Total course estimate: ~$2.7M–$3.5M
Dose modifications
There is no dose-reduction pathway. Per FDA label, the minimum infused dose is 3 × 10⁶ CD34+ cells/kg. If the manufactured product fails to meet this minimum (due to low apheresis yield or low editing efficiency), the infusion is held and a second apheresis collection is attempted. Repeat manufacturing adds another 4–6 months to the timeline. Patients undergoing repeat apheresis remain on standard SCD/TDT supportive care (transfusion, hydroxyurea, iron chelation) in the interim.
Fertility preservation
Busulfan myeloablation is gonadotoxic. All Casgevy candidates of reproductive age must receive fertility preservation counseling and access to sperm/oocyte/embryo banking before initiating busulfan. Vertex Patient Support coordinates fertility-preservation referrals. Document the fertility-preservation discussion and the patient's election in the chart and the PA packet.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Package | Use |
|---|---|---|
73310-100-01 / 73310-0100-01 |
Patient-specific cryopreserved bag of autologous CRISPR-edited CD34+ HSCs; minimum 3 × 10⁶ CD34+ cells/kg dose; cell count and lot are patient-identified | Single one-time IV infusion; product is patient-specific and not interchangeable; do not return unused product to manufacturer (the patient's own cells) |
Patient-specific NDC pattern. Like CAR-T, Zolgensma, and other autologous one-off therapies,
Casgevy ships as a patient-specific, lot-traceable bag. The carton NDC reflects the product family rather
than a fixed activity. Document the patient-identified bag lot number, CD34+ cell count, and total
administered volume from the dose-build record before posting the claim. Submit the carton-level 11-digit NDC
with N4 qualifier in the appropriate UB-04 / 837I field. Verify the current published NDC in the FDA NDC
Directory; cell-therapy NDC assignments evolve as manufacturers update labeling.
Chain-of-custody & cold-chain constraint: The patient's HSCs are collected by apheresis
at the ATC, cryopreserved, shipped to a Vertex manufacturing facility (Boston-area), CRISPR-edited and expanded
over ~4–6 months, then shipped back cryopreserved to the same ATC. Manufacturing-related cancellations
and out-of-specification products are rare but operationally significant; engage Vertex Patient Support at the
time of confirmed-eligibility (genetic confirmation + recurrent-VOC documentation + HSCT eligibility evaluation)
to lock the apheresis date and reserve manufacturing capacity.
Phase 2
Code the claim
Multi-stage encounter — apheresis (38206/0540T), busulfan conditioning, HSC infusion (J3590 + CPT 38241), and ~30–45 day inpatient engraftment monitoring. ATC-only.
Multi-stage encounter codes CPT / HCPCS verified May 2026
Casgevy is not a single-encounter J-code event. Each of the five phases has its own billable codes. The patient-specific HSC product itself bills under J3590 (NOC) with CPT 38241 administration.
Phase 1 — Apheresis HSC collection (outpatient, ~6 months pre-infusion)
| Code | Description | When to use |
|---|---|---|
38206 |
Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous | Primary apheresis code for Casgevy. Multiple collections may be required to meet the manufacturing minimum (mobilization with plerixafor + filgrastim; G-CSF is contraindicated in SCD due to VOC risk, so plerixafor monotherapy is standard for SCD patients) |
38205 |
Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; allogeneic | NOT used for Casgevy (autologous only) |
0540T |
Hematopoietic progenitor cell (HPC); HPC boost (or HPC harvest, autologous transplant) — category III | Some payers prefer the category III code for HSC-therapy-product apheresis specifically (distinct from generic autologous HSCT apheresis). Verify with payer and MAC. |
J2562 |
Injection, plerixafor, 1 mg | Mobilization agent for SCD apheresis (G-CSF is avoided due to VOC risk); bill per mg administered. For TDT, G-CSF + plerixafor combination is more typical. |
| Apheresis E/M and supportive care | Standard outpatient E/M (99202–99215) + IV fluids + pre-medication | Hydration is critical in SCD apheresis to prevent VOCs; transfusion may be required pre-apheresis to target HbS < 30% per institutional protocol |
Phase 2 — Ex vivo CRISPR manufacturing (no billable services; Vertex internal)
The 4–6 month ex vivo CRISPR/Cas9 editing, expansion, QC, and cryopreservation is performed at the Vertex manufacturing facility. There are no provider-side billable services during this window. The patient remains on standard SCD/TDT supportive care (hydroxyurea, transfusion, iron chelation) coordinated by the ATC.
Phase 3 — Busulfan myeloablative conditioning (inpatient)
| Code | Description | When to use |
|---|---|---|
J0594 |
Injection, busulfan, 1 mg | Per-mg J-code for IV busulfan. High-dose myeloablative regimen is typically over 4 days; PK-adjusted (target AUC ~5000–6000 micromol·min/L per institutional HSCT protocol). Bill total mg administered per dose-build record. |
J3490 / J3590 |
Unclassified drug; unclassified biologics | Used if J0594 is not yet active or the payer requires NOC for the busulfan conditioning regimen (rare) |
96413 / 96415 / 96417 |
Chemotherapy administration, IV infusion; initial and additional hour | Yes — appropriate for busulfan. Busulfan is cytotoxic chemotherapy used as conditioning; the chemo admin family applies (unlike the Casgevy HSC infusion itself, which is not chemo) |
| Supportive care | Anti-emetics, antibiotic / antifungal / antiviral prophylaxis, seizure prophylaxis (busulfan), VOD/SOS surveillance | Bundled into inpatient HSCT supportive-care order set; bill individual J-codes per agent (e.g., ondansetron J2405, fosaprepitant J1453, defibrotide J3490 if VOD develops) |
Phase 4 — Autologous HSC infusion (the Casgevy product itself)
| Code | Description | When to use |
|---|---|---|
J3590 |
Unclassified biologics | Primary HCPCS for the Casgevy product as of 2026. Bill 1 unit per patient-specific HSC product. Submit invoice attachment + lot number + cell count to the payer. Some MACs prefer J3490 (unclassified drugs); some hospital-outpatient settings use C9399. Verify quarterly. |
C9399 |
Unclassified drug or biological for hospital outpatient prospective payment system (HOPPS) | Used for hospital outpatient transitional pass-through claim presentation; some MACs route Casgevy product claims through C9399 in the outpatient setting before a permanent J-code is published. |
38241 |
Hematopoietic progenitor cell transplantation; autologous | Primary administration CPT for Casgevy. Bill once per HSC infusion encounter. Includes the infusion itself; does NOT include the product, the conditioning, or the supportive care. |
38240 |
Hematopoietic progenitor cell transplantation; allogeneic | NOT used for Casgevy (autologous only) |
96365 |
Therapeutic IV infusion, initial 1 hour | NOT appropriate for the HSC product itself — HSC infusions are billed under 38241 (HSCT-specific code), not the generic therapeutic IV family. 96365 may apply to other concurrent therapeutic infusions during the inpatient stay. |
79101 |
Radiopharmaceutical therapy by intravenous administration | NOT appropriate. Casgevy is not radioactive. |
Phase 5 — Engraftment monitoring (~30–45 d inpatient, then outpatient through ~1 year)
- Inpatient HSCT supportive care: bundled into the HSCT DRG; itemized for documentation only. Includes daily CBC, daily metabolic panel, daily LFTs, infectious-disease surveillance, transfusion support (RBC and platelets while autologous-edited HSCs engraft), TPN if mucositis, antibiotic / antifungal / antiviral prophylaxis, GVHD surveillance (rare in autologous setting but documented), VOD/SOS surveillance.
- Outpatient follow-up: at months 1, 2, 3, 6, 9, 12, 18, 24 and longer. Standard E/M (99214–99215) + CBC (85025) + hemoglobin electrophoresis (83020/83021) + reticulocyte count (85044) + ferritin (82728) + chemistry panel + as-indicated organ-function labs.
- Outcomes milestone reporting (months 6, 12, 24, 60): data submitted to Vertex Patient Support for outcomes-based contract milestone verification (no separate billable CPT; this is administrative documentation tied to the payer OBA).
HSC infusion is NOT chemotherapy admin. A common coding error: the busulfan conditioning is
chemo (96413 family), but the autologous HSC infusion itself (the Casgevy product) is billed under the
HSCT-specific CPT 38241, not under any chemo or generic therapeutic IV family. Keep these two separate on the
claim.
Modifiers CMS verified May 2026
JZ / JW — generally N/A for autologous patient-specific cell product
The Casgevy product is patient-specific, lot-identified, and built to deliver the patient's own CRISPR-edited HSCs. There is no physical "vial waste" in the conventional J-code sense — the entire shipped product is intended for administration to that named patient. JZ may be reported on J3590 to attest "no discarded amount," but practice varies by MAC and the NOC / per-product unit definition makes JZ/JW reporting largely moot. Confirm with your MAC.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the HSC infusion or apheresis collection (consent, extended family counseling, fertility-preservation discussion, baseline HSCT eligibility review).
340B modifiers (JG, TB)
Casgevy is dispensed through the Vertex specialty distribution channel rather than via 340B in most cases. A small number of DSH/CAH hospitals with established autologous HSCT programs may administer 340B-acquired busulfan and supportive-care drugs (the Casgevy product itself is rarely 340B). Confirm with your 340B compliance team. Outcomes-based contracts can complicate 340B reporting because the manufacturer rebate flow interacts with 340B pricing assumptions.
Contract-specific modifiers
Some commercial payers add a contract-specific modifier or claim attachment requirement to flag claims under an outcomes-based agreement (so the claim can be linked to the manufacturer's milestone-tracking dataset). Follow the payer's outcomes-based contract operational guide; Vertex Patient Support coordinates this end-to-end. The CMS CGT Access Model has standardized identifiers for sickle cell gene therapy claims for participating state Medicaid programs.
ICD-10-CM by indication FY2026 verified May 2026
Casgevy is indicated for SCD (D57.x) and transfusion-dependent β-thalassemia (D56.x). Use indication-specific codes and document recurrent VOCs (SCD) or transfusion dependence (TDT).
| Indication | ICD-10 code | Notes |
|---|---|---|
| Hb-SS disease with crisis, with vaso-occlusive crisis (VOC) | D57.00 / D57.01 | Most common SCD genotype for Casgevy eligibility; document ≥2 severe VOCs per year on optimized supportive care including hydroxyurea |
| Sickle-cell / Hb-C disease with crisis (HbSC) | D57.20x / D57.21x | Eligible per label if recurrent severe VOCs documented |
| Sickle cell / β-thalassemia (HbS-β-thal) | D57.40x / D57.41x | Eligible per label; document recurrent severe VOCs |
| Sickle-cell trait | D57.3 | NOT eligible (carrier state, not SCD) |
| β-thalassemia major (Cooley's anemia, TDT) | D56.1 | Primary code for TDT indication; document transfusion dependence (≥100 mL/kg/yr PRBCs or ≥8 transfusions/yr) and iron chelation history |
| HbE-β-thalassemia | D56.5 | Eligible per TDT label if transfusion-dependent |
| Other β-thalassemia (intermedia, non-TDT) | D56.2 / D56.3 | NOT label-eligible unless meets TDT severity criteria |
| Long-term use of iron chelator | Z79.899 | Document chelator history (deferasirox, deferoxamine, deferiprone) for TDT patients |
| History of stem cell transplant | Z94.81 | Apply post-infusion for the patient's long-term record |
| Encounter for prophylactic measures (mobilization, conditioning) | Z29.8 | Use for the apheresis mobilization and busulfan conditioning encounters as appropriate per payer mapping |
Genetic confirmation is the gating criterion. Casgevy is indicated only for patients with
genetically confirmed SCD or transfusion-dependent β-thalassemia. Documentation must include the
hemoglobinopathy genetic / hemoglobin-electrophoresis report (genotype HbSS / HbSC / HbS-β-thal for SCD;
β-thalassemia major or HbE-β-thal for TDT) plus VOC/transfusion history. Sickle-cell trait (D57.3)
and non-transfusion-dependent β-thalassemia are not eligible. Document recurrent severe
VOCs (≥2/yr for ≥2 yr on optimized supportive care including hydroxyurea) for SCD; document transfusion
burden (≥100 mL/kg/yr PRBCs or ≥8 transfusions/yr) for TDT.
Site of care & place of service Verified May 2026
Casgevy is administered exclusively at Vertex-credentialed Authorized Treatment Centers (ATCs): FACT-accredited HSCT-eligible facilities with established autologous HSCT programs, busulfan dose-banding experience, apheresis capability, and post-transplant supportive-care infrastructure. Office-based (POS 11) and ambulatory infusion center (POS 49) administration are categorically not appropriate. The dominant billing setting is hospital inpatient (POS 21) for the busulfan + HSC infusion + ~30–45 day engraftment admission, with hospital outpatient (POS 22) for the prior apheresis collection and the post-discharge follow-up.
| Setting | POS | Claim form | Eligible? |
|---|---|---|---|
| ATC hospital inpatient (busulfan + HSC infusion + engraftment admission) | 21 | UB-04 / 837I | Yes — dominant setting; HSCT DRG bundling with high-cost outlier or NTAP for the Casgevy product |
| ATC hospital outpatient (apheresis collection ~6 mo pre-infusion) | 22 | UB-04 / 837I | Yes — primary apheresis setting |
| ATC hospital outpatient (post-discharge follow-up, mo 1–24) | 22 | UB-04 / 837I | Yes — primary follow-up setting; standard outpatient E/M + labs |
| Non-ATC academic medical center | 21/22 | UB-04 | No — ATC restriction; patient must be referred to a credentialed center |
| Community hospital / non-HSCT center | 21/22 | UB-04 | No — HSCT-eligible facility required |
| Physician office | 11 | n/a | No — not appropriate for myeloablative HSCT |
| Ambulatory infusion suite (AIC) | 49 | n/a | No — ATC restriction |
| Patient home | 12 | n/a | No |
ATC certification process: Vertex credentials ATCs on FACT accreditation, autologous HSCT
program track record, busulfan PK-adjusted dosing experience, apheresis volume (SCD apheresis is operationally
distinct from oncology apheresis due to VOC risk), cryopreservation chain-of-custody, post-transplant
infectious-disease infrastructure, fertility-preservation referral network, and outcomes-data reporting
capability. Most ATCs are large academic medical centers with established BMT programs. The list is maintained
at casgevy.com/hcp. Administering at a non-ATC is the #2 cause of Casgevy claim denial.
Long inpatient stay drives total course cost. The ~30–45 day inpatient stay for
busulfan + HSC infusion + engraftment monitoring is bundled into the HSCT DRG (DRG 014-017 autologous BMT
family). The Casgevy product itself (J3590) typically triggers a high-dollar outlier payment or NTAP because
the WAC vastly exceeds the standard DRG payment. Confirm the hospital's contracted reimbursement with the
payer before the inpatient admission; uncontrolled DRG bundling without outlier payment is not financially
viable.
Claim form field mapping Vertex Patient Support 2026
Casgevy claims are typically submitted on UB-04 (837I) by the ATC. Multiple distinct encounters across the multi-stage course; each has its own claim.
| Information | UB-04 field | Notes |
|---|---|---|
| NPI (facility / rendering) | FL 56 / FL 76–79 | ATC and attending hematology / BMT physician |
| HCPCS J3590 + revenue code 0636 | FL 42 (rev code) + FL 44 (HCPCS) | Revenue code 0636 = "Drugs requiring detailed coding" for the patient-specific HSC product; some payers map to 0815 (allogeneic stem cell acquisition) or a payer-specific cell-therapy revenue code |
| Units (per product) | FL 46 | 1 unit per patient-specific HSC product (NOC; do NOT bill per cell or per mL) |
| CPT 38241 + revenue code 0815 | FL 42 (rev code) + FL 44 (CPT) | Revenue code 0815 = "Autologous stem cell acquisition"; 38241 = HSCT autologous |
| CPT 38206 + revenue code 0815 (prior encounter) | FL 42 + FL 44 | Apheresis encounter ~6 months earlier; submit as a separate UB-04 at the time of collection |
| J0594 (busulfan) + revenue code 0636 | FL 42 + FL 44 | Bill total mg per dose-build over the 4-day conditioning regimen |
| NDC qualifier + 11-digit NDC + UoM + qty | FL 43 / shaded line | N4 + product NDC + UN (unit) + 1; include patient-specific bag lot number in claim notes per payer |
| ICD-10 | FL 67 + 67A–Q | D57.x for SCD or D56.1 / D56.5 for TDT primary; Z29.8, Z79.899, Z94.81 as documented; document recurrent VOC count (SCD) or transfusion burden (TDT) |
| PA number | FL 63 | Required by all payers; document genetic confirmation, recurrent-VOC history (SCD) or transfusion dependence (TDT), prior therapy history (hydroxyurea, chelation), HSCT eligibility, ATC certification, fertility-preservation plan |
| Outcomes-based contract identifier | FL 80 / attachment | If applicable per payer; CMS CGT Access Model identifier for participating state Medicaid; flag the claim for milestone tracking (3–5 year horizon) |
| DRG (inpatient) | FL 71 | HSCT DRG family (DRG 014-017 autologous BMT) per current grouper; outlier payment or NTAP applies for the Casgevy product cost |
| Modifier (if any) | FL 44 modifier line | JZ optional per MAC; contract-specific modifier per outcomes agreement; 340B JG/TB if applicable (rare for the Casgevy product itself) |
Document the workflow timeline. Beyond the claim, the patient record must show: genetic
confirmation report, recurrent VOC history (SCD) with dates / severity / hospitalizations, hydroxyurea trial
and outcome (SCD), transfusion history and chelation log (TDT), HSCT eligibility evaluation, fertility
preservation discussion and election, ATC certification, apheresis date and yield, manufacturing dates,
busulfan dose-build and PK targets, HSC infusion date and cell count, engraftment dates (ANC ≥ 500,
platelet ≥ 20K and ≥ 50K), discharge summary, and the long-term outcomes-tracking plan. This
documentation supports the PA, the HSCT DRG, the outlier/NTAP, and the manufacturer's outcomes-based contract
milestone verification at 3–5 years.
Phase 3
Get paid
SCD / TDT genetic confirmation + recurrent VOCs / transfusion dependence + ATC certification + HSCT eligibility are the gating PA criteria. CMS CGT Access Model is the dominant Medicaid framework.
Payer policy snapshot Reviewed May 2026
Universal PA. Genetic confirmation, recurrent VOCs (SCD) or transfusion dependence (TDT), prior hydroxyurea trial, ATC certification, HSCT eligibility, and fertility-preservation plan are the universal documentation requirements.
| Payer | PA? | Key documentation requirements | Outcomes-based contract? |
|---|---|---|---|
| UnitedHealthcare Gene Therapy Medical Policy |
Yes | Age ≥ 12 yr; genetic confirmation HbSS/HbSC/HbS-β-thal (SCD) or β-thal major/HbE-β-thal (TDT); ≥2 severe VOCs/yr for SCD with documented hydroxyurea trial; transfusion dependence (≥100 mL/kg/yr PRBCs) for TDT; ATC certification; HSCT eligibility evaluation; fertility-preservation counseling; baseline organ function | Yes (Optum gene therapy benefit) |
| Aetna CPB Exagamglogene Autotemcel |
Yes | FDA-label-aligned; SCD recurrent VOCs or TDT transfusion dependence; ATC restriction; specialty review | Yes (case-by-case) |
| BCBS plans Vary by plan |
Yes | Generally aligned with FDA label and ASH / ASH-ASTCT guidelines for SCD / TDT; some Blues plans participate in CMS CGT Access Model; some have specific gene-therapy benefit pools | Common at large plans |
| Cigna / Evernorth | Yes | FDA-label-aligned; ATC; comprehensive documentation packet; Accredo specialty channel | Yes (Accredo specialty channel) |
| State Medicaid (CGT Access Model participating) | Yes | CMS Cell and Gene Therapy Access Model (launched Jan 2025); standardized outcomes metrics and pricing for SCD gene therapies (Casgevy and Lyfgenia) for participating state Medicaid programs | Yes (CMS-administered) |
| State Medicaid (non-participating) | Yes | State-specific; supplemental rebate agreements (SRA) and outcomes-based agreements common; alignment with FDA label | Common (state-specific) |
CMS Cell and Gene Therapy (CGT) Access Model
Launched January 2025, the CMS CGT Access Model is a multi-state framework in which CMS negotiates outcomes-based agreements with manufacturers of sickle cell gene therapies (Casgevy and Lyfgenia) on behalf of participating state Medicaid programs. The model standardizes outcomes metrics (severe VOC events, transfusion utilization, hospitalization), pricing structure, and milestone-tracking timelines. State Medicaid programs that opt in delegate negotiation to CMS in exchange for risk-sharing on outcomes. As of 2026 the participation roster includes >20 state Medicaid agencies and is expanding. The provider's operational impact: a standardized outcomes-data reporting workflow coordinated through Vertex Patient Support, and a CGT Access Model identifier on the inpatient claim.
Outcomes-based contracts — how they work for billers
Vertex offers outcomes-based agreements (OBAs) with most major commercial payers and the CMS CGT Access Model for participating state Medicaid. Typical structure: full WAC (~$2.2M) is paid at administration; if specified clinical milestones (e.g., absence of severe VOCs, transfusion independence) are not met over a 3–5 year horizon, a percentage of WAC is refunded by Vertex to the payer. The provider's role: document the clinical outcome data (severe VOC events, transfusion events, HbF and HbA levels, hospitalizations) at standardized intervals (months 6, 12, 24, 60). Vertex Patient Support coordinates this longitudinally. The rebate/refund flow is payer-side and does not affect the provider's payment at administration.
Step therapy & prior SCD / TDT therapy
For SCD: most payers require documented adequate trial of hydroxyurea (typically ≥6–12 months at maximum tolerated dose) with persistent recurrent severe VOCs before authorizing Casgevy. Crizanlizumab (Adakveo) and voxelotor (Oxbryta, voluntarily withdrawn 2024) trials may be requested by some payers but are not universally required after the Oxbryta withdrawal. For TDT: documented transfusion dependence and adequate chelation history (deferasirox / deferoxamine / deferiprone) is universal. Document the prior-therapy history, response, and clinical rationale for selecting Casgevy in the PA packet.
Medicare / Medicaid reimbursement CMS Q2 2026 (NOC / invoice; CGT Model active)
Most Casgevy patients are adolescent / young adult Medicaid (SCD demographics) or commercial. For inpatient HSCT administration, the Casgevy product is packaged into the HSCT DRG with high-dollar outlier payment or NTAP; the CMS CGT Access Model standardizes Medicaid pricing for participating states.
Casgevy payment framework
One-time CRISPR-edited HSC product · product payment via NOC / invoice plus HSCT DRG outlier; outcomes-based contracts and CMS CGT Model dominant
Product WAC
~$2.2M
manufacturer WAC, one-time
Total course (incl. facility)
~$2.7M–$3.5M
drug + apheresis + conditioning + 30–45 d admission
CMS CGT Model states
>20
participating state Medicaid (2026)
ASP does not apply in the conventional sense. Casgevy is a one-time patient-specific
autologous cell product with no quarterly volume-weighted utilization. CMS prices it via invoice / NOC
rather than via the quarterly ASP file. Verify the current quarter's MEDICARE_ASP entry (J3590 is an NOC
code and will not have a Casgevy-specific line). Most commercial plans and the CMS CGT Access Model use the
manufacturer WAC or a CGT-Model-negotiated price as the payment basis.
HSCT DRG packaging + outlier: When Casgevy is administered inpatient (the dominant setting),
the patient is grouped into the autologous BMT DRG family (DRG 014-017 per current MS-DRG grouper). Casgevy's
WAC vastly exceeds the standard DRG payment, so the inpatient claim almost always triggers a high-dollar
outlier payment. For Medicare, the New Technology Add-On Payment (NTAP) pathway may apply depending on
Casgevy's NTAP status for the current fiscal year; verify CMS IPPS final rule for the current FY. State
Medicaid programs have negotiated SRAs or participate in the CMS CGT Access Model for standardized pricing.
Inpatient (Medicare / Medicaid)
Casgevy is administered inpatient (busulfan conditioning + HSC infusion + 30–45 d engraftment monitoring). The HSC product cost is bundled into the assigned HSCT DRG (014-017) with outlier payment or NTAP. Confirm the hospital's contracted reimbursement with the payer before the inpatient admission; bundling without outlier is not viable. The CMS CGT Access Model provides a standardized Medicaid pricing framework for participating states.
Outpatient (Medicare / Medicaid)
The apheresis collection (~6 months pre-infusion) is the dominant outpatient encounter and is billed at the ATC under CPT 38206 (or 0540T) with revenue code 0815 (autologous stem cell acquisition). Outpatient billing of the Casgevy product itself is uncommon because of the busulfan and ~30–45 day engraftment monitoring requirement; the HOPPS Addendum B may include C9399 transitional pass-through guidance for the product in edge cases.
Coverage
No NCD specific to Casgevy or to ex vivo gene-edited HSC therapies generally. Coverage falls under MAC LCDs and payer-specific medical / pharmacy benefit policies. All MACs and major commercial payers cover Casgevy for FDA-approved on-label indications with documented genetic confirmation, recurrent VOCs (SCD) or transfusion dependence (TDT), prior hydroxyurea trial (SCD), ATC certification, and HSCT eligibility.
Code history
- J3590 — "Unclassified biologics"; used as primary HCPCS for the Casgevy product pending a permanent product-specific J-code. Verify the current CMS HCPCS quarterly file for any transition to a permanent code.
- C9399 — HOPPS transitional pass-through; used in hospital outpatient setting where applicable. New cell and gene therapies typically receive transitional C-codes before permanent J-codes.
- J3490 — "Unclassified drug"; some payers route Casgevy claims through J3490 instead of J3590; either NOC code is acceptable per payer guidance.
- Future permanent J-code: likely to be assigned in a future CMS HCPCS quarterly update; monitor the quarterly file release.
Patient assistance — Vertex Patient Support Vertex verified May 2026
- Vertex Patient Support (Casgevy): 1-877-752-5933 / casgevy.com/hcp — benefits investigation, prior authorization assistance, ATC referral, apheresis logistics, manufacturing chain-of-custody, travel and lodging coordination for the ~6-week ATC stay, fertility-preservation counseling pre-busulfan, outcomes-based contract administration, longitudinal post-infusion follow-up
- Vertex Patient Assistance Program (PAP): free product for uninsured / underinsured patients meeting income requirements; Casgevy access pathway is highly individualized given the WAC scale and the HSCT facility cost stack
- Sickle Cell Disease Association of America (SCDAA): sicklecelldisease.org — SCD advocacy, peer/family support, treatment-center directory, emergency financial assistance for travel and lodging while at the ATC, education resources
- Cooley's Anemia Foundation (CAF): thalassemia.org — TDT advocacy, peer/family support, treatment-center directory, education on chelation and HSCT
- Foundations: PAN Foundation (rare/genetic disease funds where applicable), HealthWell Foundation, Patient Advocate Foundation — primarily supplemental for non-drug costs (travel, lodging, chelation, post-transplant care); verify open SCD / thalassemia / rare-disease funds quarterly
- BMT InfoNet (bmtinfonet.org): autologous HSCT family support, transplant-center directory, post-transplant resource library
- Travel & lodging: Vertex Patient Support coordinates with Healthcare Hospitality Network, Ronald McDonald House (for adolescent patients), Hope Lodge, and ATC-affiliated patient housing for the ~6-week inpatient + outpatient ATC stay
Need to model what a specific patient's family will actually pay across the multi-stage course (apheresis,
manufacturing, conditioning, HSC infusion, 30–45 day admission, post-discharge follow-up) after copay
assistance, deductible, coinsurance, and OOP max?
Run a CareCost Estimate — J3590 pre-loaded with the multi-stage Casgevy
workflow.
Phase 4
Fix problems
Missing SCD/TDT genetic confirmation, administration at non-ATC, inadequate VOC / transfusion documentation, pediatric < 12 attempted, and missing HSCT eligibility are the top denial drivers.
Safety & FDA-label monitoring FDA label / W&P
No boxed warning on Casgevy label. This is a notable contrast with Lyfgenia (the other
sickle cell gene therapy), which carries a boxed warning for hematologic malignancy due to its lentiviral
vector. Casgevy uses CRISPR/Cas9 ribonucleoprotein editing (no integrating vector), and to date the safety
signal does not support a boxed warning. Document discussion of the absence-of-boxed-warning and the
comparator-Lyfgenia profile in the consent.
FDA-label warnings & precautions
- Prolonged cytopenias: profound neutropenia and thrombocytopenia after busulfan conditioning are expected; monitor daily CBC during the inpatient stay; manage with G-CSF (filgrastim, pegfilgrastim) and platelet transfusions per HSCT protocol.
- Infection: bacterial, fungal, and viral infection risk during the cytopenic window; antibiotic / antifungal / antiviral prophylaxis per institutional HSCT protocol (e.g., fluconazole, acyclovir, levofloxacin, micafungin per local epidemiology).
- Hepatic veno-occlusive disease / sinusoidal obstruction syndrome (VOD/SOS): busulfan conditioning carries a small but serious VOD/SOS risk; surveillance includes daily weight, daily LFTs, abdominal exam, doppler imaging if suspected; defibrotide is the standard rescue therapy.
- Engraftment failure: rare with autologous edited HSC; if neutrophil engraftment is not achieved by day +28 or platelet engraftment by day +45, consider product re-dosing (with available cryopreserved aliquot) or rescue allogeneic HSCT per institutional protocol.
- GVHD: graft-vs-host disease is rare in autologous HSCT (donor and recipient are the same patient) but documented in label; clinical vigilance during engraftment.
- Infertility: busulfan myeloablation is gonadotoxic; fertility preservation must be discussed and offered pre-treatment.
- Off-target genome editing risk (added Aug 2025 label update): per the current Casgevy label, "the risk of unintended, off-target editing in CD34+ cells due to genetic variants cannot be ruled out." This is a precaution rather than a boxed warning; it informs informed consent and long-term follow-up enrollment but does not change PA/coverage criteria.
- Late-effects long-term follow-up: Vertex Patient Support coordinates 15-year long-term follow-up registry per FDA REMS-like postmarketing commitment; monitor for secondary malignancy, off-target editing effects, organ-function trajectories.
- Vaccinations: live vaccines are deferred during the early post-transplant immune reconstitution window per ASH-ASTCT post-HSCT immunization guidelines; coordinate with infectious disease.
Outcomes-based milestone tracking
Beyond the FDA-label safety monitoring, the manufacturer's outcomes-based contract and the CMS CGT Access Model require documentation of clinical milestones at months 6, 12, 24, and 60 post-infusion. For SCD: absence of severe vaso-occlusive crises, hospitalization rate, transfusion utilization, HbF and HbA levels. For TDT: transfusion independence (commonly defined as no PRBC transfusion for ≥12 months), HbA levels. Standardized outcomes-data instruments are coordinated through Vertex Patient Support.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| SCD / TDT genetic confirmation missing | PA submitted without hemoglobinopathy genotyping report or hemoglobin electrophoresis confirming HbSS / HbSC / HbS-β-thal (SCD) or β-thal major / HbE-β-thal (TDT) | Submit genetic / electrophoresis report confirming the specific genotype. Sickle-cell trait (D57.3) and non-transfusion-dependent β-thalassemia are not eligible. This is the #1 cause of Casgevy denial. |
| Administration at non-ATC facility | Patient routed to a facility not on Vertex's Authorized Treatment Center (ATC) list | Re-route the patient to a credentialed ATC; Vertex Patient Support maintains the directory at casgevy.com/hcp. Non-ATC facilities cannot order or administer Casgevy. #2 cause of denial. |
| Recurrent VOC documentation gaps (SCD) | PA packet does not document ≥2 severe vaso-occlusive crises per year on optimized supportive care including hydroxyurea | Submit detailed VOC log: dates, severity, hospitalizations, ED visits, exchange transfusions, opioid utilization. Document hydroxyurea trial (dose, duration, response, HbF response). #3 cause of denial. |
| TDT severity not documented | PA packet does not document transfusion dependence (≥100 mL/kg/yr PRBCs or ≥8 transfusions/yr) and chelation history | Submit transfusion log (date, volume, indication), ferritin / liver iron / cardiac iron trajectories, chelation history (deferasirox / deferoxamine / deferiprone), and clinical rationale for HSCT. #4 cause of denial. |
| Patient < 12 years | Pediatric patient attempted despite FDA label cutoff of ≥12 yr | Casgevy is not FDA-approved for patients < 12 yr. Maintain on standard SCD/TDT supportive care until eligibility age. #5 cause of denial. |
| HSCT eligibility evaluation incomplete | PA packet missing transplant-eligibility workup (cardiac, pulmonary, hepatic, renal function; infectious-disease screen; PFTs; ECHO; psychosocial) | Complete the standard pre-HSCT eligibility evaluation per ATC protocol; document all organ-function and psychosocial criteria. #6 cause of denial. |
| Hydroxyurea trial not documented (SCD) | PA packet does not document an adequate hydroxyurea trial (≥6–12 months at maximum tolerated dose) with persistent recurrent VOCs | Document hydroxyurea dose, duration, response (HbF, ANC, MCV), and the persistent-VOC rationale for escalating to Casgevy. |
| Fertility-preservation plan not documented | PA packet missing fertility-preservation counseling for a patient of reproductive age before busulfan myeloablation | Document fertility-preservation discussion and patient election (sperm banking, oocyte / embryo cryopreservation, or declined with rationale). Vertex Patient Support coordinates referrals. |
| Wrong HCPCS (J9999, A9999, etc.) | Claim submitted under an inappropriate unclassified code | Resubmit under J3590 (unclassified biologics) or C9399 (HOPPS transitional pass-through) per payer guidance. J3490 may also be acceptable. Submit invoice attachment + patient-specific lot number + cell count. |
| Wrong admin CPT (96365 therapeutic IV instead of 38241 HSCT) | Coder applied generic IV admin family instead of HSCT-specific admin code | Resubmit with CPT 38241 (autologous HSCT) for the Casgevy product infusion. 96365 is not appropriate for HSC products. |
| Outcomes-based contract flag missing | Inpatient claim not linked to the OBA or CMS CGT Access Model milestone-tracking dataset | Apply the payer's outcomes-based contract identifier or the CMS CGT Access Model identifier per the contract operational guide; coordinate with Vertex Patient Support. Without the OBA flag, the manufacturer rebate / CGT Model rebate flow may break. |
Frequently asked questions
Is Casgevy a one-time treatment?
Yes. Casgevy is administered as a single one-time IV infusion of autologous CRISPR-edited CD34+ HSCs after busulfan myeloablative conditioning. There is no repeat or maintenance dose. The edited HSCs engraft in the bone marrow and produce HbF-expressing red cells for life. The full course is a multi-stage encounter spanning apheresis collection, ex vivo manufacturing, busulfan conditioning, HSC infusion, and ~30–45 days of inpatient engraftment monitoring.
What is the HCPCS code for Casgevy?
As of 2026, Casgevy has no permanent product-specific J-code. Most claims are billed under
J3590 (unclassified biologics) or C9399 (HOPPS transitional pass-through) with
invoice-based pricing. Some payers accept J3490 (unclassified drugs). The autologous HSC
infusion is billed under CPT 38241 (HSCT autologous), and apheresis collection under
38206 or 0540T. Verify with your MAC and the current CMS HCPCS quarterly file
because cell and gene therapy coding evolves rapidly.
What is the #1 cause of Casgevy denial?
Missing genetic confirmation of SCD or TDT. The Casgevy label requires documented genetic confirmation of the underlying hemoglobinopathy (HbSS / HbSC / HbS-β-thal for SCD; β-thal major / HbE-β-thal for TDT) plus recurrent severe VOC history (SCD) or transfusion dependence (TDT). PA submissions without the genotyping report, hemoglobin electrophoresis, or detailed VOC / transfusion-history documentation are denied at intake.
Casgevy vs Lyfgenia — which to choose?
Both are autologous ex vivo modified HSC therapies for sickle cell disease. Casgevy uses CRISPR/Cas9 editing of the BCL11A enhancer (restores HbF) and has no boxed warning. Lyfgenia uses lentiviral transduction adding a modified β-globin transgene (bA-T87Q) and has a boxed warning for hematologic malignancy. Both share the same multi-stage HSCT workflow, busulfan myeloablation, ~30–45 day inpatient stay, and similar list price ($2.2M Casgevy vs $3.1M Lyfgenia). Most payers cover both; some plans prefer Casgevy because of the cleaner safety label. A patient can only receive one course of one product per lifetime.
How does Casgevy differ from AAV gene therapies like Zolgensma?
Mechanism and billing pathway are completely different. AAV gene therapies (Zolgensma, Hemgenix, Roctavian) deliver a transgene in vivo via an AAV vector; billing is a single infusion encounter under one J-code + 96365 admin. Casgevy is ex vivo gene editing: HSCs collected by apheresis, shipped to a manufacturing facility, CRISPR-edited over ~4–6 months, then reinfused after busulfan myeloablation. Billing is a multi-stage encounter (apheresis 38206 + busulfan J0594 + HSC infusion J3590 + CPT 38241 + ~30–45 d inpatient).
Why is busulfan myeloablation required?
Casgevy is an autologous HSC product. For the edited HSCs to engraft in the bone marrow and produce HbF-expressing red cells for life, the patient's existing (sickle-cell or β-thalassemia) hematopoietic compartment must first be cleared. High-dose busulfan myeloablative conditioning (typically 4 days, PK-adjusted) achieves this. Myeloablation is more intense than CAR-T's lymphodepletive conditioning (fludarabine + cyclophosphamide), which is why the Casgevy inpatient stay is 30–45 days while CAR-T is typically 7–14 days. Busulfan carries risks of VOD/SOS, prolonged cytopenias, infection, infertility, and a small long-term malignancy risk.
What is an Authorized Treatment Center (ATC)?
Vertex credentials a network of ATCs that are the only sites permitted to administer Casgevy. ATCs are FACT-accredited HSCT-eligible facilities with established autologous HSCT programs, busulfan dose-banding experience, apheresis capability, cryopreservation infrastructure, and post-transplant supportive-care capacity. The list is maintained at casgevy.com/hcp. Non-ATC facilities cannot order Casgevy. This is the #2 cause of Casgevy claim denials.
How long is the apheresis-to-infusion timeline?
Typically 4–6 months for ex vivo CRISPR manufacturing alone, plus pre-apheresis evaluation and HSCT eligibility workup (~1–2 months) and pre-infusion conditioning admission (~1 week). Total apheresis-to-infusion timeline is typically 6–9 months. Repeat apheresis (if first manufacturing run fails to meet the 3 × 10⁶ CD34+/kg minimum) adds another 4–6 months. Patients remain on standard SCD/TDT supportive care (hydroxyurea, transfusion, iron chelation) throughout.
What is the CMS Cell and Gene Therapy (CGT) Access Model?
Launched January 2025, the CMS CGT Access Model is a multi-state framework in which CMS negotiates outcomes-based agreements with manufacturers of sickle cell gene therapies (Casgevy and Lyfgenia) on behalf of participating state Medicaid programs. The model standardizes outcomes metrics, pricing, and milestone tracking. As of 2026 the participation roster includes >20 state Medicaid agencies and is expanding. Provider impact: a standardized outcomes-data reporting workflow coordinated through Vertex Patient Support, and a CGT Access Model identifier on the inpatient claim for participating states.
What about fertility preservation?
Busulfan myeloablation is gonadotoxic. All Casgevy candidates of reproductive age must receive fertility-preservation counseling and access to sperm, oocyte, or embryo banking before initiating busulfan. Vertex Patient Support coordinates fertility-preservation referrals. Document the discussion and the patient's election (or declined-with-rationale) in the chart and the PA packet.
How does outcomes-based contracting work for Casgevy billers?
Vertex offers outcomes-based agreements (OBAs) to commercial payers and participates in the CMS CGT Access Model for participating state Medicaid. Full WAC is paid at administration; if specified milestones (absence of severe VOCs for SCD; transfusion independence for TDT) are not met over a 3–5 year horizon, a percentage of WAC is refunded by Vertex to the payer. The provider organization is not party to the rebate flow but documents the clinical outcome data (severe VOC events, transfusion events, HbF and HbA levels, hospitalizations) at months 6, 12, 24, 60. Vertex Patient Support coordinates the longitudinal data flow.
Cost: how does $2.7M–$3.5M get paid for?
Through payer contracts, not patient out-of-pocket. Most patients are Medicaid (SCD demographics skew young and Medicaid-insured) or commercial. State Medicaid uses SRAs or the CMS CGT Access Model. Commercial payers use a combination of standard medical benefit + stop-loss reinsurance + outcomes-based contracts + benefit-pool carve-outs. Patient family OOP exposure is typically capped at the plan's OOP maximum, not the WAC. Vertex Patient Support and copay-assistance foundations help bridge any residual exposure.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- DailyMed — CASGEVY prescribing information (BLA 125787, setid 7c3e12ad-e2fe-4d3f-a630-ea7364d9e846; current label rev. Mar 30, 2026)
- DailyMed — CASGEVY (exagamglogene autotemcel)
- Vertex — Casgevy professional / Patient Support site
- FDA press release — First gene therapies for sickle cell disease (Dec 8, 2023)
- CMS — Medicare Part B Drug ASP Pricing File
- CMS Innovation Center — Cell and Gene Therapy Access Model
- CMS — MS-DRG classifications (DRG 014-017 autologous BMT)
- Frangoul et al., NEJM 2021 — CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
- Frangoul et al., NEJM 2024 — Exagamglogene autotemcel for severe sickle cell disease (CLIMB SCD-121)
- Locatelli et al., NEJM 2024 — Exagamglogene autotemcel for transfusion-dependent β-thalassemia (CLIMB THAL-111)
- Sickle Cell Disease Association of America (SCDAA)
- Cooley's Anemia Foundation
- American Society of Hematology — SCD practice guidelines
- FACT — Foundation for the Accreditation of Cellular Therapy
- UnitedHealthcare — Casgevy Medical Drug Policy
- Aetna CPB — Exagamglogene Autotemcel
- FDA National Drug Code Directory
- CMS — JW/JZ modifier policy (CR 12056, eff. July 2023)
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP / OPPS status indicator | Quarterly | Auto-bound to CareCost ASP layer; OPPS Addendum B reviewed each calendar quarter. J3590 is NOC; product priced via invoice / NOC and the CMS CGT Access Model. |
| Payer policies (UHC, Aetna, BCBS, Cigna, state Medicaid, CMS CGT Model) | Semi-annual | Manual review against published payer policy documents; outcomes-based contract terms reviewed annually with Vertex Patient Support. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases; monitor for transition from J3590 NOC to a permanent product-specific J-code. |
| NDC, dosing, FDA label, warnings & precautions, monitoring schedule | Event-driven | Tied to manufacturer document version + FDA label revision date. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS, Vertex,
ASH, FACT, pivotal trial publications — all linked above). Editorial review in progress. Until that
review is complete, treat this as a draft reference and verify each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026 (J3590 priced via NOC / invoice; not in standard ASP layer). First CRISPR-edited gene therapy page in the CareCost catalog. Manufacturer source: Vertex Patient Support 2026. Five-way comparison vs Lyfgenia (lentiviral HSC), Zolgensma (J3399 AAV9), Hemgenix (J1411 AAV5 hemophilia B), and Roctavian (J1412 AAV5 hemophilia A). Multi-stage encounter (apheresis -> manufacturing -> busulfan conditioning -> HSC infusion -> engraftment monitoring) documented. CMS CGT Access Model (active Jan 2025) referenced for participating state Medicaid programs.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File and the OPPS Addendum B status indicator (where applicable; J3590 is NOC and Casgevy is commonly priced via invoice and the CMS CGT Access Model for participating state Medicaid). Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indications, dosing, busulfan conditioning, and monitoring schedule are verified against the current FDA label revision. Outcomes-based contracting and CMS CGT Access Model context are verified against Vertex Patient Support operational guidance and CMS Innovation Center publications. We do not paraphrase from billing-software vendor blogs.